EGF receptor inhibition alleviates hyperuricemic nephropathy

Journal of the American Society of Nephrology

Volumn 26, Issue 11, 2015, Pages 2716-2729

  Liu, Na ^a   Wang, Li ^a   Yang, Tao ^a   Xiong, Chongxiang ^b   Xu, Liuqing ^a   Shi, Yingfeng ^a   Bao, Wenfang ^a   Chin, Y Eugene ^c   Cheng, Shi Bin ^d   Yan, Haidong ^a   Qiu, Andong ^e   Zhuang, Shougang ^a,b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BROWN UNIVERSITY   (United States)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^d BROWN UNIVERSITY   (United States)

^e TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ALPHA SMOOTH MUSCLE ACTIN; CHLORDANE; COLLAGEN TYPE 1; CREATININE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; OTERACIL POTASSIUM; RANTES; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; URIC ACID; XANTHINE OXIDASE; CHEMOKINE; CYTOKINE; QUINAZOLINE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; FEEDING; GLOMERULOSCLEROSIS; HYPERURICEMIA; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; URIC ACID NEPHROPATHY; URIC ACID URINE LEVEL; URINALYSIS; URINARY EXCRETION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DISEASE COURSE; FIBROBLAST; FIBROSIS; INFLAMMATION; KIDNEY; KIDNEY DISEASE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RISK FACTOR; SPRAGUE DAWLEY RAT;

ANIMALS; CHEMOKINES; CYTOKINES; DISEASE PROGRESSION; FIBROBLASTS; FIBROSIS; HYPERURICEMIA; INFLAMMATION; KIDNEY; KIDNEY DISEASES; MALE; PHOSPHORYLATION; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; URIC ACID;

EID: 84946037645     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014080793     Document Type: Article

References (70)

1. Jalal DI, Chonchol M, Chen W, Targher G: Uric acid as a target of therapy in CKD. Am J Kidney Dis 61: 134-146, 2013
2. Jin M, Yang F, Yang I, Yin Y, Luo JJ, Wang H, Yang XF: Uric acid, hyperuricemia and vascular diseases. Front Biosci (Landmark Ed) 17: 656 669, 2012
3. Choi JW, Ford ES, Gao X, Choi HK: Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: The Third National Health and Nutrition Examination Survey. Arthritis Rheum 59: 109-116, 2008
4. Yoo TW, Sung KC, Shin HS, Kim BJ, Kim BS, Kang JH, LeeMH, Park JR, Kim H, Rhee EJ, Lee WY, Kim SW, Ryu SH, Keum DG: Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 69: 928-933, 2005
5. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA: Hyperuricemia and risk of stroke: A systematic review and meta-analysis. Arthritis Rheum 61: 885-892, 2009
6. Lu Z, Dong B, Wu H, Chen T, Zhang Y, Wu J, Xiao H: Serum uric acid level in primary hypertension among Chinese nonagenarians/centenarians. J Hum Hypertens 23: 113-121, 2009
7. Feig DI, Kang DH, Johnson RJ: Uric acid and cardiovascular risk.NEngl J Med 359: 1811-1821, 2008
8. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA: Hyperuricemia and coronary heart disease: A systematic review and metaanalysis. Arthritis Care Res (Hoboken) 62: 170-180, 2010
9. Shi Y, ChenW, Jalal D, Li Z, Chen W,Mao H, Yang Q, Johnson RJ, Yu X: Clinical outcome of hyperuricemia in IgA nephropathy: A retrospective cohort study and randomized controlled trial. Kidney Blood Press Res 35: 153-160, 2012
10. Madero M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, Collins AJ, Levey AS,Menon V: Uric acid and long-term outcomes in CKD. Am J Kidney Dis 53: 796-803, 2009
11. Sonoda H, Takase H, Dohi Y, Kimura G: Uric acid levels predict future development of chronic kidney disease. Am J Nephrol 33: 352-357, 2011
12. Wang S, Shu Z, Tao Q, Yu C, Zhan S, Li L: Uric acid and incident chronic kidney disease in a large health check-up population in Taiwan. Nephrology (Carlton) 16: 767-776, 2011
13. Mok Y, Lee SJ, Kim MS, CuiW, Moon YM, Jee SH: Serum uric acid and chronic kidney disease: The Severance cohort study. Nephrol Dial Transplant 27: 1831-1835, 2012
14. Hovind P, Rossing P, TarnowL, Johnson RJ, ParvingHH: Serumuric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: An inception cohort study. Diabetes 58: 1668-1671, 2009
15. Jalal DI, Rivard CJ, Johnson RJ, Maahs DM,McFann K, RewersM, Snell Bergeon JK: Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: Findings from the Coronary Artery Calcification in Type 1 Diabetes study. Nephrol Dial Transplant 25: 1865-1869, 2010
16. Anzai N, Kanai Y, Endou H: New insights into renal transport of urate. Curr Opin Rheumatol 19: 151-157, 2007
17. Hagos Y, Stein D, Ugele B, Burckhardt G, Bahn A: Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J Am Soc Nephrol 18: 430-439, 2007
18. Uchino H, Tamai I, Yamashita K, Minemoto Y, Sai Y, Yabuuchi H, Miyamoto K, Takeda E, Tsuji A: p-aminohippuric acid transport at renal apical membrane mediated by human inorganic phosphate transporter NPT1. Biochem Biophys Res Commun 270: 254-259, 2000
19. Van Aubel RA, Smeets PH, van den Heuvel JJ, Russel FG: Human organic anion transporterMRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am J Physiol Renal Physiol 288: F327-F333, 2005
20. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38: 1101-1106, 2001
21. Sánchez-Lozada LG, Tapia E, López-Molina R, Nepomuceno T, Soto V, Avila-Casado C, Nakagawa T, Johnson RJ, Herrera-Acosta J, FrancoM: Effects of acute and chronic L-arginine treatment in experimental hyperuricemia. Am J Physiol Renal Physiol 292: F1238-F1244, 2007
22. Umekawa T, Chegini N, Khan SR: Increased expression of monocyte chemoattractant protein-1 (MCP-1) by renal epithelial cells in culture on exposure to calciumoxalate, phosphate and uric acid crystals. Nephrol Dial Transplant 18: 664-669, 2003
23. Long CL, Qin XC, Pan ZY, Chen K, Zhang YF, CuiWY, Liu GS, Wang H: Activation of ATP-sensitive potassium channels protects vascular endothelial cells from hypertension and renal injury induced by hyperuricemia. J Hypertens 26: 2326-2338, 2008
24. Gude D, Chennamsetty S, Jha R: Fathoming uric acid nephropathy. Saudi J Kidney Dis Transpl 24: 1259-1261, 2013
25. Ryu ES, KimMJ, Shin HS, Jang YH, Choi HS, Jo I, Johnson RJ, Kang DH: Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. Am J Physiol Renal Physiol 304: F471-F480, 2013
26. Wang Y, Bao X: Effects of uric acid on endothelial dysfunction in early chronic kidney disease and its mechanisms. Eur J Med Res 18: 26, 2013
27. Rao GN, Corson MA, Berk BC: Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 266: 8604-8608, 1991
28. Kanellis J,Watanabe S, Li JH, Kang DH, Li P, Nakagawa T,Wamsley A, Sheikh-Hamad D, Lan HY, Feng L, Johnson RJ: Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase 2. Hypertension 41: 1287-1293, 2003
29. Mulay SR, Evan A, Anders HJ: Molecular mechanisms of crystal-related kidney inflammation and injury. Implications for cholesterol embolism, crystalline nephropathies and kidney stone disease. Nephrol Dial Transplant 29: 507-514, 2014
30. Li YC, Ding XS, Li HM, Zhang Y, Bao J: Role of G protein-coupled estrogen receptor 1 in modulating transforming growth factor-b stimulated mesangial cell extracellular matrix synthesis and migration. Mol Cell Endocrinol 391: 50-59, 2014
31. Terashima H, Kato M, EbisawaM, Kobayashi H, Suzuki K, Nezu Y, Sada T: R-268712, an orally active transforming growth factor-b type I receptor inhibitor, prevents glomerular sclerosis in a Thy1 nephritis model. Eur J Pharmacol 734: 60-66, 2014
32. Zheng D, Wen L, Li C, Peng A, Cao Q, Wang Y, Harris D: Adoptive transfer of bone marrow dendritic cells failed to localize in the renal cortex and to improve renal injury in adriamycin nephropathy. Nephron, Exp Nephrol 126: 8-15, 2014
33. Liu Y: Renal fibrosis: New insights into the pathogenesis and therapeutics. Kidney Int 69: 213-217, 2006
34. Böttinger EP: TGF-beta in renal injury and disease. Semin Nephrol 27: 309-320, 2007
35. Joo CK, Kim HS, Park JY, Seomun Y, Son MJ, Kim JT: Ligand releaseindependent transactivation of epidermal growth factor receptor by transforming growth factor-beta involves multiple signaling pathways. Oncogene 27: 614-628, 2008
36. Lee E, Yi JY, Chung E, Son Y: Transforming growth factor beta(1) transactivates EGFR via an H(2)O(2)-dependent mechanism in squamous carcinoma cell line. Cancer Lett 290: 43-48, 2010
37. Lautrette A, Li S, Alili R, Sunnarborg SW, BurtinM, Lee DC, Friedlander G, Terzi F: Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: A new therapeutic approach. Nat Med 11: 867-874, 2005
38. Chahdi A, Sorokin A: Endothelin-1 induces p66Shc activation through EGF receptor transactivation: Role of beta(1)Pix/Galpha(i3) interaction. Cell Signal 22: 325-329, 2010
39. Hua H, Munk S, Whiteside CI: Endothelin-1 activates mesangial cell ERK1/2 via EGF-receptor transactivation and caveolin-1 interaction. Am J Physiol Renal Physiol 284: F303-F312, 2003
40. Uchiyama-Tanaka Y, Matsubara H, Nozawa Y, Murasawa S, Mori Y, Kosaki A, Maruyama K, Masaki H, Shibasaki Y, Fujiyama S, Nose A, Iba O, Hasagawa T, Tateishi E, Higashiyama S, Iwasaka T: Angiotensin II signaling and HB-EGF shedding via metalloproteinase in glomerular mesangial cells. Kidney Int 60: 2153-2163, 2001
41. Tang L, Li H, Gou R, Cheng G, Guo Y, Fang Y, Chen F: Endothelin-1 mediated high glucose-induced epithelial-mesenchymal transition in renal tubular cells. Diabetes Res Clin Pract 104: 176-182, 2014
42. Sagar SK, Zhang C, Guo Q, Yi R; Lin-Tang: Role of expression of endothelin-1 and angiotensin-II and hypoxia-inducible factor-1a in the kidney tissues of patients with diabetic nephropathy. Saudi J Kidney Dis Transpl 24: 959-964, 2013
43. Zhou TB, Qin YH, Lei FY, Huang WF, Drummen GP: Association of prohibitin-1 and 2 with oxidative stress in rats with renal interstitial fibrosis. Mol Biol Rep 41: 3033-3043, 2014
44. Flamant M, Tharaux PL, Placier S, Henrion D, Coffman T, Chatziantoniou C, Dussaule JC: Epidermal growth factor receptor trans-activationmediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic mice. FASEB J 17: 327-329, 2003
45. Chen J, Chen JK, Nagai K, Plieth D, Tan M, Lee TC, Threadgill DW, Neilson EG, Harris RC: EGFR signaling promotes TGFb-dependent renal fibrosis. J Am Soc Nephrol 23: 215-224, 2012
46. Liu N, Guo JK, Pang M, Tolbert E, Ponnusamy M, Gong R, Bayliss G, Dworkin LD, Yan H, Zhuang S: Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis. J Am Soc Nephrol 23: 854-867, 2012
47. Zeng F, Singh AB, Harris RC: The role of the EGF family of ligands and receptors in renal development, physiology and pathophysiology. Exp Cell Res 315: 602-610, 2009
48. François H, Placier S, Flamant M, Tharaux PL, Chansel D, Dussaule JC, Chatziantoniou C: Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition. FASEB J 18: 926-928, 2004
49. Viau A, El Karoui K, Laouari D, Burtin M, Nguyen C, Mori K, Pillebout E, Berger T, Mak TW, Knebelmann B, Friedlander G, Barasch J, Terzi F: Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J Clin Invest 120: 4065-4076, 2010
50. Yang HT, Yim H, Cho YS, Kym D, Hur J, Kim JH, Chun W, Kim HS: Assessment of biochemical markers in the early post-burn period for predicting acute kidney injury and mortality in patients with major burn injury: Comparison of serum creatinine, serum cystatin-C, plasma and urine neutrophil gelatinase-associated lipocalin. Crit Care 18: R151, 2014
51. Lin SL, Kisseleva T, Brenner DA, Duffield JS: Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 173: 1617 1627, 2008
52. Kim SM, Choi YW, Seok HY, Jeong KH, Lee SH, Lee TW, Ihm CG, Lim SJ, Moon JY: Reducing serum uric acid attenuates TGF-b1-induced profibrogenic progression in type 2 diabetic nephropathy. Nephron, Exp Nephrol 121: e109-e121, 2012
53. Zhang Y, Huang XR, Wei LH, Chung AC, Yu CM, Lan HY: miR-29b as a therapeutic agent for angiotensin II-induced cardiac fibrosis by targeting TGF-b/Smad3 signaling. Mol Ther 22: 974-985, 2014
54. Huang H, Liu Y, Daniluk J, Gaiser S, Chu J,Wang H, Li ZS, Logsdon CD, Ji B: Activation of nuclear factor-kB in acinar cells increases the severity of pancreatitis in mice. Gastroenterology 144: 202-210, 2013
55. Gong R, Rifai A, Tolbert EM, Biswas P, Centracchio JN, Dworkin LD: Hepatocyte growth factor ameliorates renal interstitial inflammation in rat remnant kidney by modulating tubular expression of macrophage chemoattractant protein-1 and RANTES. J Am Soc Nephrol 15: 2868 2881, 2004
56. Liu N, He S, Tolbert E, Gong R, Bayliss G, Zhuang S: Suramin alleviates glomerular injury and inflammation in the remnant kidney. PLoSONE 7: e36194, 2012
57. Hediger MA, Johnson RJ, Miyazaki H, Endou H: Molecular physiology of urate transport. Physiology (Bethesda) 20: 125-133, 2005
58. Sun S, Ning X, Zhai Y,Du R, Lu Y, He L, Li R,WuW, SunW,Wang H: Egr 1 mediates chronic hypoxia-induced renal interstitial fibrosis via the PKC/ERK pathway. Am J Nephrol 39: 436-448, 2014
59. Tang J, Liu N, Zhuang S: Role of epidermal growth factor receptor in acute and chronic kidney injury. Kidney Int 83: 804-810, 2013
60. Liu-Bryan R, Scott P, Sydlaske A, Rose DM, Terkeltaub R: Innate immunity conferred by Toll-like receptors 2 and 4 andmyeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystalinduced inflammation. Arthritis Rheum 52: 2936-2946, 2005
61. Tang J, Liu N, Tolbert E, PonnusamyM,Ma L, Gong R, BaylissG, Yan H, Zhuang S: Sustained activation of EGFR triggers renal fibrogenesis after acute kidney injury. Am J Pathol 183: 160-172, 2013
62. PangM, Ma L,Gong R, Tolbert E,Mao H, PonnusamyM, Chin YE, Yan H, Dworkin LD, Zhuang S: A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney Int 78: 257-268, 2010
63. Mónica Torres A, Mac Laughlin M, Muller A, Brandoni A, Anzai N, EndouH: Altered renal elimination of organic anions in rats with chronic renal failure. Biochim Biophys Acta 1740: 29-37, 2005
64. Hayashi S, Fujiwara S, Noguchi T: Evolution of urate-degrading enzymes in animal peroxisomes. Cell BiochemBiophys 32: 123-129, 2000
65. Hediger MA: [Physiology and biochemistry of uric acid]. Ther Umsch 61: 541-545, 2004
66. Kratzer JT, LanaspaMA,MurphyMN, Cicerchi C,Graves CL, Tipton PA, Ortlund EA, Johnson RJ, Gaucher EA: Evolutionary history and metabolic insights of ancient mammalian uricases. Proc Natl Acad Sci U S A 111: 3763-3768, 2014
67. Wu XW, Muzny DM, Lee CC, Caskey CT: Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 34: 78-84, 1992
68. Johnson RJ,Nakagawa T, Jalal D, Sánchez-Lozada LG, Kang DH, Ritz E: Uric acid and chronic kidney disease:Which is chasing which? Nephrol Dial Transplant 28: 2221-2228, 2013
69. Sánchez-Lozada LG, Tapia E, Santamaría J, Avila-Casado C, Soto V, Nepomuceno T, Rodríguez-Iturbe B, Johnson RJ, Herrera-Acosta J: Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 67: 237 247, 2005
70. Bose B, Badve SV, Hiremath SS, Boudville N, Brown FG, Cass A, de Zoysa JR, Fassett RG, Faull R, Harris DC, Hawley CM, Kanellis J, Palmer SC, Perkovic V, Pascoe EM, Rangan GK,Walker RJ,WaltersG, Johnson DW: Effects of uric acid-lowering therapy on renal outcomes: Asystematic review and meta-analysis. NephrolDial Transplant 29: 406 413, 2014